Drug
Choline fenofibrate clinical trials
Also written ABT-335 and TriLipix.
- studies test it
- 19
- open now
- 1
- in phase 3
- 9
- first study started
- 2006
Keep track of what changes. Save the choline fenofibrate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2008 (8)
| Year | Studies |
|---|---|
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 8 |
| 2009 | 3 |
| 2015 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
- Phase 3
- 9
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 5
Abbott (7) · AstraZeneca (4) · AbbVie (prior sponsor, Abbott) (1) · Chong Kun Dang Pharmaceutical (1) · University of Pennsylvania (1) · Abbott Products (1) · Radiant Research (1) · Seoul National University Bundang Hospital (1)
Often tested with
Tested in the same studies.
Rosuvastatin (5) · Atorvastatin (3) · Fenofibric acid (3) · Niacin (1) · Warfarin (1) · Ezetimibe (1) · Simvastatin (1)
Studies
Open first, then newest update. How each study uses choline fenofibrate is read from its arms, and is right about nine times in ten.
Testing it · 19
- Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined DyslipidemiaRecruitingPhase 4Seoul National University Bundang HospitalNCT05365425Written as Choline fenofibrate
- AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary AtherosclerosisWithdrawnPhase 3Piedmont HealthcareNCT01030328Written as TriLipix
- Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the BloodCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT00616772Written as ABT-335
- CKD-337(2) Drug-drug Interaction StudyCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02422030Written as Trilipix 135mg
- Study of Trilipix Effects on Lipids and ArteriesTerminatedPhase 4University of UtahNCT01025492Written as Trilipix
- Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility StudyCompletedPhase 2University of PennsylvaniaNCT00728910Written as ABT335
- 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney DiseaseCompletedPhase 3AstraZenecaNCT00680017Written as ABT-335 plus rosuvastatin
- A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With DyslipidemiaCompletedPhase 3AstraZenecaNCT00463606Written as ABT-335 and rosuvastatin calcium
- Interaction Between ABT-335, Rosuvastatin and WarfarinCompletedPhase 1AstraZenecaNCT00487136Written as warfarin plus ABT-335 plus rosuvastatin 5 mg
- Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered ConcomitantlyCompletedPhase 1AstraZenecaNCT00585143Written as ABT-335
- Effect of Choline Fenofibrate (SLV348) on Macular EdemaCompletedPhase 2Abbott ProductsNCT00683176Written as Choline Fenofibrate
- Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the BloodCompletedPhase 3AbbottNCT00639158Written as ABT-335
- ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) StudyCompletedPhase 1/2Radiant ResearchNCT00673881Written as choline fenofibrate
- A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and EzetimibeCompletedPhase 1AbbottNCT00681525Written as ABT-335
- Comparison of Fenofibric Acid Bioavailability From ABT-335 CapsulesCompletedPhase 1AbbottNCT00839293Written as ABT-335
- Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.CompletedPhase 3AbbottNCT00300430Written as ABT-335 and rosuvastatin calcium
- Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedPhase 3AbbottNCT00300482Written as ABT-335
- Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedPhase 3AbbottNCT00300469Written as ABT-335
- Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedPhase 3AbbottNCT00300456Written as ABT-335
Given in every arm · 1 — choline fenofibrate is usual care beside what is tested
As the comparator · 4 — what is tested is compared with choline fenofibrate
- Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.CompletedPhase 1AstraZenecaNCT00728780Written as ABT-335 and rosuvastatin
- Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mgCompletedPhase 1AstraZenecaNCT00826358Written as ABT-335
- Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin CalciumCompletedPhase 1AstraZenecaNCT00681395Written as ABT-335
- Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin CalciumCompletedPhase 1AstraZenecaNCT00808678Written as ABT-335
Codes
What other systems call choline fenofibrate · ClinicalTrials.gg INT005353
- UNII (FDA) 4BMH7IZT98CHOLINE FENOFIBRATEConfirmed FDA, Wikidata
- RxNorm 1433887Confirmed FDA, Wikidata
- Wikidata Q27259379choline fenofibrateConfirmed FDA, Wikidata
- NCI Thesaurus C75253Choline FenofibrateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4BMH7IZT98 | CHOLINE FENOFIBRATE | Confirmed FDA, Wikidata |
| RxNorm | 1433887 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27259379 | choline fenofibrate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C75253 | Choline Fenofibrate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.